On this episode of BloodStream, hosts Patrick James Lynch and Amy Board share stories of remarkable achievement and progress in bleeding disorders. Hear from Tim Stowers, a severe hemophilia A patient who has completed solo channel swims, as he shares his journey of resilience and determination. Plus, get the latest updates on Star Therapeutics' lead VWD therapy, now entering a pivotal Phase 3 trial, and learn how patients can help shape the first validated VWD quality-of-life assessment tool.

Presenting Sponsor:

Takeda, visit bleedingdisorders.com to learn more.

Show Notes:

Star's Pivotal Phase 3 Study (VIVID-6) Initiated:

VGA039 is the first subcutaneous therapy, dosed once monthly, that has the potential to address all types of VWD and all types of bleeds. It has also received Fast Track and orphan drug designation from the United States Food and Drug Administration (FDA). The additional investment announced today supports our continued global clinical expansion as we advance into our pivotal, Phase 3 trial.

Explore clinical trial eligibility: visit THIS WEBSITE

To participate in the first validated VWD quality of life patient-reported outcome tool, please e-mail Judith.Monickaraj@chet.rochester.edu to learn more.

Subscribe:

The BloodStream Podcast

Connect with BloodStream Media:

BloodStreamMedia.com

BloodStream on Facebook

BloodStream on X/Twitter

BloodStream on Instagram

BloodStream on LinkedIn

BloodStream on TikTok

Kickstart Your Weekend with Mary Kennedy